Table 1 Demographic (N = 488).

From: Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy

 

GNRI < 92 (n = 102)

GNRI ≥ 92 (n = 386)

P-value

Gender

  

0.846

 Male

44 (43.1%)

160 (41.5%)

 

 Female

58 (56.9%)

226 (58.5%)

 

Age

70.0 (63.8–76.0)

67.0 (58.0–76.0)

0.023*

BMI (kg/m2)

22.9 (19.9–24.7)

24.2 (21.8–26.2)

 < 0.001**

Albumin (g/dL)

3.1 (2.9–3.3)

4.0 (3.8–4.3)

 < 0.001**

GNRI

86.8 (83.4–89.3)

101.3 (96.9–104.3)

 < 0.001**

Performance status ECOG

  

0.002**

 0

14 (13.7%)

49 (12.7%)

 

 1

58 (56.9%)

279 (72.3%)

 

 2–4

30 (29.4%)

58 (15.0%)

 

Comorbidity

HTN

65 (63.7%)

233 (60.4%)

0.613

DM

27 (26.5%)

78 (20.2%)

0.217

COPD/asthema

5 (4.9%)

12 (3.1%)

0.369

CAD

6 (5.9%)

13 (3.4%)

0.252

Creatinine > 1.5 mg/dL

30 (29.4%)

99 (25.6%)

0.522

HBV or HCV carrier

14 (13.7%)

42 (10.9%)

0.531

Previous UCUB

21 (20.6%)

66 (17.1%)

0.501

Hydronephrosis

11 (10.8%)

39 (10.1%)

0.986

Smoking status

  

0.695

 Never

77 (75.5%)

284 (73.6%)

 

 Current/former

25 (24.5%)

102 (26.4%)

 

Preoperative renal function

  

0.157

 eGFR ≥ 30 ml/min/1.73m2

71 (69.6%)

295 (76.4%)

 

 eGFR < 30 ml/min/1.73m2

31 (30.4%)

91 (23.6%)

 

History of uremia

  

0.887

 Negative

86 (84.3%)

330 (85.5%)

 

 Positive

16 (15.7%)

56 (14.5%)

 

Surgical modality

  

0.187

 Open

19 (18.6%)

48 (12.4%)

 

 Transperitoneal laparoscopy

78 (76.5%)

325 (84.2%)

 

 Retroperitoneoscopy

5 (4.9%)

13 (3.4%)

 

Tumor ___location

Calyx

24 (23.5%)

90 (23.3%)

1.000

Renal pelvis

56 (54.9%)

241 (62.4%)

0.203

Promixal ureter

40 (39.2%)

120 (31.1%)

0.151

Middle ureter

29 (28.4%)

80 (20.7%)

0.126

Distal ureter

22 (21.6%)

97 (25.1%)

0.538

Surgical margin

  

0.026*

 Negative

85 (83.3%)

353 (91.5%)

 

 Positive

17 (16.7%)

33 (8.5%)

 

Pathological T

  

0.067

 T1

46 (45.1%)

204 (52.8%)

 

 T2

13 (12.7%)

46 (11.9%)

 

 T3

30 (29.4%)

115 (29.8%)

 

 T4

13 (12.7%)

21 (5.4%)

 

Pathological N

  

 < 0.001**

 N0

83 (81.4%)

362 (93.8%)

 

 N1

5 (4.9%)

11 (2.8%)

 

 N2–3

14 (13.7%)

13 (3.4%)

 

Tumor grade

  

0.090

 Low

5 (4.9%)

40 (10.4%)

 

 High

97 (95.1%)

346 (89.6%)

 

Concomitant CIS

  

0.082

 Negative

79 (77.5%)

329 (85.2%)

 

 Positive

23 (22.5%)

57 (14.8%)

 

Lymphovascular invasion

  

0.001**

 Negative

67 (66.3%)

314 (81.3%)

 

 Positive

35 (34.3%)

72 (18.7%)

 

Adjuvant Chemotherapy

25 (24.5%)

92 (23.8%)

0.991

F/u time (month)

23.2 (11.3–36.1)

41.2 (27.0–65.0)

 < 0.001**

  1. GNRI geriatric nutritional risk index, BMI body mass index, ECOG Eastern Cooperative Oncology Group, HTN hypertension, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, CAD coronary artery disease, HBV Hepatitis B virus, HCV Hepatitis C virus, UCUB urothelial carcinoma in urinary bladder, eGFR estimated Glomerular filtration rate, CIS carcinoma in situ.
  2. Chi-square test. Mann–Whitney Test, Median (IQR). *P < 0.05, **P < 0.01.
Back to article page